Physician profile
Mark Tuttle
NPI 1194737130
$611.82
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $510 · 2022: $14.39 · 2023: $87.27.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $87.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $87.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $101.66 | 2022-2023 | Corevalve Evolut R |
| Glaxosmithkline, LLC. | $89.56 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.66 | 2019 | |
| Merck Sharp & Dohme LLC | $59.66 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $54.81 | 2019 | |
| Novo Nordisk INC | $54.65 | 2019 | |
| Mdd US Operations, LLC | $54.10 | 2019 | |
| Pfizer INC. | $27.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $19.41 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.71 | 2019 | |
| Lilly USA, LLC | $14.58 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.88 | 2019 | |
| Mylan Specialty L.P. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Tuttle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.